Top 20 Monoclonal Antibodies of 2025 

Shots: 

• Redefining treatment paradigms, monoclonal antibody therapies utilize advanced mechanisms of action to provide care across multiple therapeutic areas 

• As of 2024, the global monoclonal antibody therapy market was valued at $252.6B and is projected to reach $497.5B by 2029, growing at a CAGR of 14.5%. Keytruda leads the market with $29.48B in revenue, followed by Dupixent and Skyrizi, generating $13.61B and $11.71B, respectively 

• PharmaShots presents a concise analysis of the Top 20 Monoclonal Antibodies of 2025 

Note: Columns 1 and 2 represent ranks and brand names of mAb, while Columns 3, 4, and 5 showcase the total revenue of 2023, the total revenue of 2024, and the percentage change. 

20. Proprietary Name: Xolair 

Non-Proprietary Name: Omalizumab 

Company: Roche 

First Approved: US (Jun 20, 2003), EU (Oct 25, 2005) 

Total Revenue: $2.73B 

• Xolair is prescribed for Asthma, chronic rhinosinusitis with Nasal Polyps, Chronic Spontaneous Urticaria, and IgE-Mediated Food Allergy 

• Xolair is a humanized IgG1 monoclonal antibody that binds to free IgE in blood and interstitial fluid and to membrane-bound IgE on B lymphocytes 

• Xolair’s 2024 revenue increased by 5.78% as compared to 2023, due to higher sales worldwide. In February 2024, the US FDA approved Xolair as a medicine for children and adults with IgE-mediated food allergy 

19. Proprietary Name: US (Actemra), EU (RoActemra) 

Non-Proprietary Name: Tocilizumab 

Company: Roche 

First Approved: US (Jan 8, 2010), EU (Jan 16, 2009) 

Total Revenue: $2.92B 

• Actemra is a humanized monoclonal antibody indicated to treat Rheumatoid Arthritis, Giant Cell Arteritis, Systemic Sclerosis-associated Interstitial Lung Disease, Polyarticular Juvenile Idiopathic Arthritis, Systemic Juvenile Idiopathic Arthritis, Cytokine Release Syndrome, and Coronavirus Disease 2019 (COVID-19). In the US, it is approved by the name Actemra, while in the EU, it is marketed as RoActemra 

• Actemra binds to both soluble and membrane-bound IL-6 receptors and inhibits IL-6-mediated signaling pathways 

• Actemra’s total 2024 sales decreased by 6.28% as compared to 2023, due to the impact of biosimilar and generic competition. In October 2024, Health Canada approved Fresenius Kabi’s tocilizumab biosimilar, Tyenne 

18. Proprietary Name: Taltz 

Non-Proprietary Name: Ixekizumab 

Company: Eli Lilly 

First Approved: US (Mar 22, 2016), EU (Apr 25, 2016) 

Total Revenue: $3.26B 

• Taltz is a humanized monoclonal antibody that is prescribed to treat Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis, Non-radiographic Axial and Spondyloarthritis 

• Taltz binds to the interleukin 17A (IL-17A) cytokine and neutralizes it thus reducing inflammation 

• In 2024, Taltz showed an increase of 18.16% as compared to 2023, driven by higher realized prices due to changes in estimates for rebates and discounts, as well as increased demand 

17. Proprietary Name: Tremfya 

Non-Proprietary Name: Guselkumab 

Company: Janssen Pharmaceuticals (Johnson & Johnson) 

First Approved: US (Jul 13, 2017), EU (Nov 10, 2017) 

Total Revenue: $3.67B 

• Tremfya is an IL-23 antagonist indicated for the treatment of Plaque Psoriasis, Psoriatic Arthritis, Ulcerative Colitis, and Crohn’s Disease 

• Tremfya inhibits a natural substance in the body called interleukin-23, involved in inflammatory and immune responses 

• In 2024, Tremfya generated 16.51% more revenue compared to 2023, due to market growth and share gains. In September 2024, the US FDA approved Tremfya for ulcerative colitis 

16. Proprietary Name: Ultomiris 

Non-Proprietary Name: Ravulizumab 

Company: AstraZeneca 

First Approved: US (Dec 21, 2018), EU (Jul 02, 2019) 

Total Revenue: $3.92B 

• Ultomiris is a terminal complement inhibitor indicated for the treatment of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disorder 

• Ultomiris attaches to the C5 protein, which is part of the complement system. By attaching to the C5 protein, Ultomiris blocks its effect and thereby reduces the destruction of red blood cells 

• In 2024, Ultomiris’ revenue increased by 33.24% compared to 2023, owing to high sales in the US and conversion from Soliris. In March 2024, Ultomiris was approved by the US FDA for the treatment of adults with AQP4 Ab+ NMOSD 

15. Proprietary Name: Perjeta 

Non-Proprietary Name: Pertuzumab 

Company: Roche 

First Approved: US (Jun 08, 2012), EU (Mar 04, 2013) 

Total Revenue: $4B 

• Perjeta is a humanized monoclonal antibody indicated to treat HER2+ metastatic breast cancer 

• Perjeta targets the extracellular dimerization domain (Subdomain II) of the HER2 protein and blocks ligand-dependent heterodimerization of HER2 and other HER family members, including EGFR, HER2, and HER4 

• In 2024, Perjeta’s total sales decreased by 10.6% vs. 2023, due to lower sales in Europe and Japan 

14. Proprietary Name: Vabysmo 

Non-Proprietary Name: Faricimab-svoa 

Company: Genentech (Roche) 

First Approved: US (Jan 28, 2022), EU (Sep 19, 2022) 

Total Revenue: $4.27B  

• Vabysmo is a bispecific antibody designed for the eye, approved for the treatment of Neovascular (Wet) Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO) 

• Vabysmo targets and inhibits both Angiopoietin-2 (Ang-2) and Vascular Endothelial Growth Factor-A (VEGF-A), pathways implicated in retinal vascular leakage, inflammation, and abnormal angiogenesis 

• Vabysmo’s 2024 revenue increased by 52.5% compared to 2023, reflecting strong global uptake and increased adoption across approved indications. In June 2024, Roche reported 4-year results from the AVONELLE-X trial in wet AMD, showing durable disease control, with nearly 80% of patients on extended dosing by study end 

13. Proprietary Name: Prolia 

Non-Proprietary Name: Denosumab 

Company: Amgen 

First Approved: US (Jun 01, 2010), EU (May 26, 2010) 

Total Revenue: $4.37B 

• Prolia is a RANK ligand (RANKL) inhibitor indicated to treat bone loss in women with Breast Cancer, bone loss in men with prostate cancer, osteoporosis, postmenopausal osteoporosis, and glucocorticoid-induced osteoporosis  

• Prolia binds to RANKL and prevents it from activating its receptor RANK on the surface of osteoclasts and their precursors. Prevention of the RANKL/RANK interaction inhibits osteoclast formation, function, and survival, thereby decreasing bone resorption and increasing bone mass and strength in both cortical and trabecular bone  

• In 2024, Prolia’s revenue increased by 7.98% vs. 2023, primarily driven by volume growth and high net selling price 

12. Proprietary Name: Imfinzi 

Non-Proprietary Name: Durvalumab 

Company: AstraZeneca 

First Approved: US (May 01, 2017), EU (Sep 21, 2018) 

Total Revenue: $4.71B

• Imfinzi is indicated to treat Non-small Cell Lung Cancer, Small Cell Lung Cancer, Biliary Tract Cancer, Hepatocellular Carcinoma, Endometrial Cancer, and Bladder Cancer  

• Imfinzi attaches to the protein PD-L1, i.e., located on the surface of cancer cells, and enhances the immune system’s capacity to target cancer cells by binding to PD-L1 and blocking its effects, thereby slowing disease progression  

• In 2024, Imfinzi’s revenue increased by 11.32% compared to 2023, due to increased demand in the market. In August 2024, Imfinzi in combination with chemotherapy was approved in the US for the treatment of adult patients with resectable early-stage NSCLC    

11. Proprietary Name: Hemlibra 

Non-Proprietary Name: Emicizumab 

Company: Roche 

First Approved: US (Nov 16, 2017), EU (Feb 23, 2018) 

Total Revenue: $4.98B 

• Hemlibra is a bispecific factor IXa- and factor X-directed antibody, indicated to reduce the frequency of bleeding episodes in patients with Hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors  

• Hemlibra bridges activated factor IX and factor X to restore the function of missing activated factor VIII required for effective hemostasis  

• In 2024, Hemlibra’s revenue increased by 1.19% compared to 2023, mainly due to increased sales in the US and Japan 

10. Proprietary Name: Entyvio 

Non-Proprietary Name: Vedolizumab 

Company: Takeda 

First Approved: US (May 20, 2014), EU (May 22, 2014) 

Total Revenue: $5.59B 

• Entyvio is a humanized monoclonal antibody indicated for Crohn’s Disease and Ulcerative Colitis  

• Entyvio specifically binds to the α4β7 integrin, blocks the interaction of α4β7 integrin with mucosal address cell adhesion molecule-1 (MAdCAM-1), and inhibits the migration of memory T-lymphocytes across the endothelium into inflamed gastrointestinal parenchymal tissue  

• Entyvio’s 2024 revenue increased by 1.91% as compared to 2023, due to overall increased sales. In April 2024, the US FDA approved subcutaneous Entyvio for maintenance therapy in moderately to severely active Crohn’s disease 

9. Proprietary Name: Cosentyx 

Non-Proprietary Name: Secukinumab 

Company: Novartis 

First Approved: US (Jan 21, 2015), EU (Jan 14, 2015) 

Total Revenue: $6.14B  

• Cosentyx is a human IgG1 monoclonal antibody, indicated to treat Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis, Non-Radiographic Axial Spondyloarthritis, Enthesitis-Related Arthritis, Hidradenitis Suppurativa 

• Cosentyx is a selective interleukin-17A (IL-17A) inhibitor that works by selectively binding to the IL-17A cytokine and inhibiting its interaction with the IL-17 receptor 

• In 2024, the revenue of Cosentyx increased by 23.51% vs 2023. Sales grew mainly in the US, emerging growth markets, and Europe, driven by strong demand from launches and volume growth in core indications 

8. Proprietary Name: Ocrevus 

Non-Proprietary Name: Ocrelizumab 

Company: Roche 

First Approved: US (Mar 28, 2017), EU (Jan 08, 2018) 

Total Revenue: $7.46B 

• Ocrevus is a humanized monoclonal antibody prescribed for both relapsing and primary progressive forms of multiple sclerosis 

• Ocrevus targets CD20-positive B cells, an immune cell type believed to have a significant contribution to Myelin and Axonal damage. It triggers antibody-dependent cellular cytolysis and complement-mediated lysis 

• In 2024, Ocrevus sales showed a decline of 1.47% as compared to 2023; the sales increased in CHF but showed a decline in USD conversion 

7. Proprietary Name: Humira 

Non-Proprietary Name: Adalimumab 

Company: AbbVie 

First Approved: US (Dec 31, 2002), EU (Sep 8, 2003) 

Total Revenue: $8.99B 

• Humira is prescribed as a subcutaneous injection to treat Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn’s Disease, Ulcerative Colitis, Plaque Psoriasis, Hidradenitis Suppurativa, and Uveitis 

• Humira is a tumor necrosis factor (TNF) blocker that reduces inflammation by targeting and blocking TNF-α 

• Humira’s 2024 revenue showed a decline of 37.54% as compared to 2023, primarily driven by direct biosimilar competition following the loss of exclusivity on January 31, 2023 

6. Proprietary Name: Opdivo 

Non-Proprietary Name: Nivolumab 

Company: Bristol-Myers Squibb 

First Approved: US (Mar 4, 2015), EU (Jun 19, 2015) 

Total Revenue:  $9.3B 

• Opdivo is a PD-1 blocking monoclonal antibody, approved to treat Melanoma, Non-Small Cell Lung Cancer, Malignant Pleural Mesothelioma, Renal Cell Carcinoma, Classical Hodgkin Lymphoma, Squamous Cell Carcinoma of the Head and Neck, Urothelial Carcinoma, Colorectal Cancer, Hepatocellular Carcinoma, Esophageal Cancer, Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma 

• Opdivo is prescribed as an IV injection and subcutaneous (Opdivo Qvantig). This PD-1 immune checkpoint inhibitor controls the body’s immune system to help restore the anti-tumor immune response   

• In 2024, Opdivo’s total sales increased by 3.21% as compared to 2023, owing to higher average net selling prices and demand in the US 

5. Proprietary Name: Stelara 

Non-Proprietary Name: Ustekinumab 

Company: Janssen Pharmaceutical (Johnson & Johnson) 

First Approved: US (Sep 25, 2009), EU (Jan 15, 2009) 

Total Revenue: $10.36B 

• Stelara is a human monoclonal antibody approved for the treatment of Plaque Psoriasis, Psoriatic Arthritis, Crohn’s Disease, and Ulcerative Colitis 

• Stelara selectively targets and binds to p40 protein subunits of IL-12 and IL-23, blocking the inflammatory signal pathways responsible for the conditions 

• Stelara 2024 revenue showed a decline of 4.61% compared to 2023, driven by share loss primarily due to the European biosimilar entrants 

4. Proprietary Name: Darzalex 

Non-Proprietary Name: Daratumumab 

Company: Janssen Pharmaceuticals (Johnson & Johnson) 

First Approved: US (Nov 16, 2015), EU (May 20, 2016) 

Total Revenue: $11.67B 

• Darzalex is a human anti-CD38 monoclonal antibody prescribed for the treatment of Multiple Myeloma  

• Darzalex binds to CD38 and causes cell apoptosis through antibody-dependent cellular cytotoxicity, complement-dependent toxicity, inhibition of mitochondrial transfer, or antibody-dependent cellular phagocytosis  

• Darzalex’s 2024 revenue increased by 19.87% as compared to 2023, due to high sales reported globally. In September 2024, the Darzalex-based quadruplet regimen received a CHMP positive opinion in transplant-eligible newly diagnosed multiple myeloma patients 

3. Proprietary Name: Skyrizi 

Non-Proprietary Name: Risankizumab 

Company: AbbVie 

First Approved: US (Apr 23, 2019, EU (Apr 26, 2019) 

Total Revenue:  $11.71B 

• Skyrizi is an interleukin-23 (IL-23) inhibitor available in both subcutaneous and IV forms. Skyrizi is prescribed for Plaque Psoriasis, Psoriatic Arthritis, Ulcerative Colitis, and Crohn’s disease 

• Skyrizi works by selectively blocking IL-23 by binding it to its p19 subunit. IL-23 is a naturally occurring cytokine, involved in Inflammatory and Immune responses 

• In 2024, Skyrizi’s total sales increased by 51.01% compared to 2023, primarily driven by continued strong market share uptake as well as market growth across all indications. In June 2024, the US FDA approved Skyrizi for Ulcerative Colitis, expanding AbbVie’s IBD options

2. Proprietary Name: Dupixent 

Non-Proprietary Name: Dupilumab 

Company: Sanofi and Regeneron 

First Approved: US (Mar 28, 2017), EU (Sep 26, 2017) 

Total Revenue: $13.61B 

• Dupixent is a monoclonal antibody that is prescribed as a subcutaneous injection to treat Atopic Dermatitis, Asthma, Chronic Rhinosinusitis with Nasal Polyposis, Eosinophilic Esophagitis, Prurigo Nodularis, Chronic Obstructive Pulmonary Disease, Chronic Spontaneous Urticaria, Bullous Pemphigoid 

• Dupixent is available as a single-dose pre-filled pen along with a single-dose pre-filled syringe. Dupixent inhibits the signalling of the IL-4 and IL-13 pathways    

• Dupixent’s revenue in 2024 increased by 15.13% as compared to 2023, due to higher sales in Europe and the United States. In September 2024, the US FDA approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with inadequately controlled COPD and an eosinophilic phenotype 

1. Proprietary Name: Keytruda 

Non-Proprietary Name: Pembrolizumab 

Company: Merck & Co. 

First Approved: US (Sep 04, 2014), EU (Jul 17, 2015) 

Total Revenue: $29.48B 

• Keytruda is a human PD-1 blocking antibody approved across 20 indications, Melanoma, Non-Small Cell Lung Cancer, Malignant Pleural Mesothelioma, Head and Neck Squamous Cell Carcinoma, Classical Hodgkin Lymphoma, Primary Mediastinal Large B-Cell Lymphoma, Urothelial Carcinoma, Microsatellite Instability-High or Mismatch Repair Deficient Solid Tumors, Colorectal Cancer, Gastric Cancer, Esophageal Cancer, Cervical Cancer, Hepatocellular Carcinoma, Biliary Tract Cancer, Merkel Cell Carcinoma, Renal Cell Carcinoma, Endometrial Carcinoma, Tumor Mutational Burden-High Cancer, Cutaneous Squamous Cell Carcinoma, Triple-Negative Breast Cancer 

• Keytruda blocks the interaction between PD-1 and its ligands (PD-L1 and PD-L2), which activates T-lymphocytes that may affect both the tumor cells and healthy cells  

• In 2024, Keytruda’s net sales rose by 17.86% compared to 2023 due to increased demand across the multiple approved metastatic indications. In November 2024, Japan’s MHLW approved Keytruda in combination with chemoradiotherapy as treatment for patients with locally advanced cervical cancer, based on the KEYNOTE-A18 study 

Sources:        

• Annual reports      

• SEC Filings      

• Press releases      

• Company websites      

Currency Conversion: Oanda (£1 – $1.25, €1 – $1.04, kr.1 – 0.13, CHF 1 – 1.1; Dec 31, 2024)      

Related Posts: Top 20 Monoclonal Antibodies of 2024